20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Adaptive Biotechnologies Corp (ADPT) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Seattle, United States with about 624 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, ADPT reported $277M in revenue and ($59M) in net income.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Interactive charts & full statements → Open the ADPT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $308M | $277M | $179M | $170M | $185M | $154M | $98M | $85M | $56M | $38M |
| Gross Profit | $232M | $206M | $107M | $95M | $127M | $105M | $76M | $63M | $36M | $23M |
| Gross Margin % | 75.4% | 74.2% | 59.7% | 55.6% | 68.8% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating Income (EBIT) | ($37M) | ($57M) | ($163M) | ($227M) | ($200M) | ($209M) | ($153M) | ($78M) | ($50M) | ($44M) |
| Operating Margin % | -12.2% | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.2% | -89.4% | -115.7% |
| Net Income | ($64M) | ($59M) | ($159M) | ($225M) | ($200M) | ($207M) | ($146M) | ($69M) | ($46M) | ($43M) |
| Net Margin % | -20.7% | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.7% | -83.4% | -111.4% |
| EBITDA | ($16M) | ($30M) | ($129M) | ($189M) | ($175M) | ($193M) | ($144M) | ($71M) | ($44M) | ($38M) |
| Earnings Per Share (EPS) | $-0.41 | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-0.55 | $-0.44 | $-0.41 |
| Shares Outstanding (M) | 158M | 152M | 147M | 144M | 143M | 140M | 131M | 124M | 105M | 105M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $72M | $71M | $72M | $94M | $59M | $52M | $47M | $46M |
| Gross Profit | $51M | $52M | $53M | $76M | $41M | $35M | $29M | $30M |
| Gross Margin % | 71.2% | 73.6% | 74.6% | 80.7% | 69.4% | 67.6% | 62.0% | 64.1% |
| Operating Income (EBIT) | ($16M) | ($19M) | ($13M) | $10M | ($25M) | ($30M) | ($34M) | ($33M) |
| Operating Margin % | -22.0% | -27.1% | -17.8% | 10.9% | -42.5% | -56.5% | -71.3% | -70.3% |
| Net Income | ($40M) | ($20M) | ($14M) | $10M | ($26M) | ($30M) | ($34M) | ($32M) |
| Net Margin % | -55.6% | -28.3% | -18.9% | 10.2% | -43.5% | -56.9% | -71.0% | -69.1% |
| EBITDA | ($12M) | ($14M) | ($6M) | $17M | ($18M) | ($30M) | ($26M) | ($25M) |
| Earnings Per Share (EPS) | $-0.25 | $-0.13 | $-0.09 | $0.06 | $-0.17 | $-0.20 | $-0.23 | $-0.22 |
| Shares Outstanding (M) | 158M | 156M | 153M | 163M | 152M | 149M | 147M | 148M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($21M) | ($46M) | ($95M) | ($156M) | ($184M) | ($193M) | ($150M) | $205M | ($32M) | ($35M) |
| Capital Expenditures (CapEx) | $3M | $3M | $4M | $11M | $16M | $62M | $19M | $11M | $6M | $3M |
| Free Cash Flow (FCF) | ($24M) | ($49M) | ($99M) | ($167M) | ($200M) | ($254M) | ($168M) | $194M | ($39M) | ($37M) |
| FCF Margin % | -7.8% | -17.7% | -55.2% | -98.1% | -108.1% | -164.9% | -171.3% | 228.3% | -69.3% | -97.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($6M) | ($10M) | $2M | ($7M) | ($12M) | ($28M) | ($12M) | ($27M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $0M | $1M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($8M) | ($10M) | $1M | ($8M) | ($13M) | ($30M) | ($13M) | ($27M) |
| FCF Margin % | -10.6% | -14.6% | 2.0% | -8.0% | -22.2% | -56.7% | -26.5% | -59.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $641M | $513M | $539M | $661M | $857M | $923M | $1.1B | $912M | $333M | $362M |
| Cash & Cash Equivalents | $170M | $70M | $48M | $65M | $90M | $139M | $123M | $97M | $55M | $85M |
| Total Liabilities | $490M | $288M | $337M | $353M | $393M | $319M | $373M | $341M | $591M | $587M |
| Total Debt (Short + Long-Term) | $9M | $14M | $10M | $9M | $9M | $5M | $4M | $0M | $0M | $0M |
| Total Shareholders' Equity | $143M | $219M | $203M | $308M | $464M | $604M | $743M | $571M | ($258M) | ($225M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ADPT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms